Dr. Galsky on the rationale for the CheckMate 274 trial in urothelial carcinoma

Matthew Galsky, MD, discusses the rationale for the CheckMate 274 Phase 3 trial in urothelial cancer.

Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, Icahn School of Medicine, Mount Sinai; co-director of the Bladder Cancer Center of Excellence and associate director for translational research at the Tisch Cancer Institute, discusses the rationale for the Phase 3 CheckMate 274 (NCT02632409) trial in urothelial cancer.

CheckMate 274 evaluated adjuvant nivolumab (Opdivo) versus placebo in patients with high-risk muscle-invasive urothelial cancer. Long-term data showed nivolumab maintained disease-free survival benefit on placebo.

Radical surgery remains a standard treatment for muscle-invasive urothelial cancer, which involves removing the bladder for bladder cancer or removing the kidney and ureter for upper urinary tract cancer, Galsky says. Despite surgery, a large subset of patients will still develop metastatic recurrence, Galsky says.

CheckMate 274 explored the use of adjuvant nivolumab as a systemic treatment to potentially reduce the risk of recurrence, Galsky concludes.

Comments are closed.